These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Chronicity index, especially glomerular sclerosis, is the most powerful predictor of renal response following immunosuppressive treatment in patients with lupus nephritis. Park DJ; Choi SE; Xu H; Kang JH; Lee KE; Lee JS; Choi YD; Lee SS Int J Rheum Dis; 2018 Feb; 21(2):458-467. PubMed ID: 29314776 [TBL] [Abstract][Full Text] [Related]
3. Comparison of Lupus Nephritis Induction Treatments in a Hispanic Population: A Single-center Cohort Analysis. Mejía-Vilet JM; Arreola-Guerra JM; Córdova-Sánchez BM; Morales-Buenrostro LE; Uribe-Uribe NO; Correa-Rotter R J Rheumatol; 2015 Nov; 42(11):2082-91. PubMed ID: 26373566 [TBL] [Abstract][Full Text] [Related]
4. Retrospective analysis of nephritis response and renal outcome in a cohort of 928 Egyptian lupus nephritis patients: a university hospital experience. Momtaz M; Fayed A; Wadie M; Gamal SM; Ghoniem SA; Sobhy N; Kamal Elden NM; Hamza WM Lupus; 2017 Dec; 26(14):1564-1570. PubMed ID: 28625079 [TBL] [Abstract][Full Text] [Related]
5. Predictive factors for low rate of remission in a population of Colombian patients with severe proliferative lupus nephritis. Pinto-Peñaranda LF; Duque-Caballero V; Márquez-Hernández JD; Muñoz-Grajales C; Velásquez-Franco CJ Clin Rheumatol; 2015 May; 34(5):897-903. PubMed ID: 25592376 [TBL] [Abstract][Full Text] [Related]
6. Immunosuppressive therapy withdrawal after remission achievement in patients with lupus nephritis. Zen M; Fuzzi E; Loredo Martinez M; Depascale R; Fredi M; Gatto M; Larosa M; Saccon F; Iaccarino L; Doria A Rheumatology (Oxford); 2022 Feb; 61(2):688-695. PubMed ID: 33909900 [TBL] [Abstract][Full Text] [Related]
7. The prognosis of biopsy-proven lupus nephritis in chinese patients: long term follow-up of 86 cases. Shen K; Yu Y; Tang Z; Liu Z; Li L Chin Med J (Engl); 1997 Jul; 110(7):502-7. PubMed ID: 9594205 [TBL] [Abstract][Full Text] [Related]
8. High-dose azathioprine pulse therapy as a new treatment option in patients with active Wegener's granulomatosis and lupus nephritis refractory or intolerant to cyclophosphamide. Benenson E; Fries JW; Heilig B; Pollok M; Rubbert A Clin Rheumatol; 2005 Jun; 24(3):251-7. PubMed ID: 15940558 [TBL] [Abstract][Full Text] [Related]
9. European evidence-based recommendations for the diagnosis and treatment of childhood-onset lupus nephritis: the SHARE initiative. Groot N; de Graeff N; Marks SD; Brogan P; Avcin T; Bader-Meunier B; Dolezalova P; Feldman BM; Kone-Paut I; Lahdenne P; McCann L; Özen S; Pilkington CA; Ravelli A; Royen-Kerkhof AV; Uziel Y; Vastert BJ; Wulffraat NM; Beresford MW; Kamphuis S Ann Rheum Dis; 2017 Dec; 76(12):1965-1973. PubMed ID: 28877866 [TBL] [Abstract][Full Text] [Related]
10. Outcome of lupus nephritis in childhood onset SLE in North and Central India: single-centre experience over 25 years. Srivastava P; Abujam B; Misra R; Lawrence A; Agarwal V; Aggarwal A Lupus; 2016 Apr; 25(5):547-57. PubMed ID: 26637291 [TBL] [Abstract][Full Text] [Related]
11. Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide. Houssiau FA; Vasconcelos C; D'Cruz D; Sebastiani GD; Garrido Ed Ede R; Danieli MG; Abramovicz D; Blockmans D; Mathieu A; Direskeneli H; Galeazzi M; Gül A; Levy Y; Petera P; Popovic R; Petrovic R; Sinico RA; Cattaneo R; Font J; Depresseux G; Cosyns JP; Cervera R Arthritis Rheum; 2002 Aug; 46(8):2121-31. PubMed ID: 12209517 [TBL] [Abstract][Full Text] [Related]
14. Outcome and prognostic indicators of diffuse proliferative lupus glomerulonephritis treated with sequential oral cyclophosphamide and azathioprine. Mok CC; Ho CT; Chan KW; Lau CS; Wong RW Arthritis Rheum; 2002 Apr; 46(4):1003-13. PubMed ID: 11953978 [TBL] [Abstract][Full Text] [Related]
15. Comparative clinical prospective therapeutic study between cyclophosphamide, cyclosporine and azathioprine in the treatment of lupus nephritis. El-Sehemy MS; Al-Saaran AM; Baddour NM; Adam AG; Moez PE Egypt J Immunol; 2006; 13(1):39-52. PubMed ID: 17974149 [TBL] [Abstract][Full Text] [Related]
16. Use of cyclophosphamide and other immunosuppressive drugs in the treatment of patients with lupus nephritis. Brugos B; Sebestyen L; Tarr T; Vincze Z Pharmazie; 2014 Jun; 69(6):442-4. PubMed ID: 24974578 [TBL] [Abstract][Full Text] [Related]
17. Azathioprine/methylprednisolone versus cyclophosphamide in proliferative lupus nephritis. A randomized controlled trial. Grootscholten C; Ligtenberg G; Hagen EC; van den Wall Bake AW; de Glas-Vos JW; Bijl M; Assmann KJ; Bruijn JA; Weening JJ; van Houwelingen HC; Derksen RH; Berden JH; Kidney Int; 2006 Aug; 70(4):732-42. PubMed ID: 16820790 [TBL] [Abstract][Full Text] [Related]
18. Clinicopathological findings, treatment response and predictors of long-term outcome in a cohort of lupus nephritis patients managed according to the Euro-lupus regime: a retrospective analysis in Sri Lanka. Herath N; Ratnatunga N; Weerakoon K; Wazil A; Nanayakkara N BMC Res Notes; 2017 Feb; 10(1):80. PubMed ID: 28148285 [TBL] [Abstract][Full Text] [Related]
19. Predictors of renal relapse in Korean patients with lupus nephritis who achieved remission six months following induction therapy. Moon SJ; Park HS; Kwok SK; Ju JH; Choi BS; Park KS; Min JK; Kim HY; Park SH Lupus; 2013 Apr; 22(5):527-37. PubMed ID: 23423249 [TBL] [Abstract][Full Text] [Related]
20. Treatment and renal outcome of lupus nephritis: single center experience. Go KW; Teo SM Med J Malaysia; 2006 Oct; 61(4):447-50. PubMed ID: 17243522 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]